Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US

References

• WuEQShiLBirnbaumHHudsonTKesslerRAnnual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approachPsychol Med200636111535154016907994
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGShiLThe economic burden of schizophrenia in the United States in 2002J Clin Psychiatry20056691122112916187769
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDEFuriakNMMontgomeryWMedication adherence levels and differential use of mental-health services in the treatment of schizophreniaBMC Res Notes20092619138402
   PubMedGoogle Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of InterventionEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• dosReisSJohnsonESteinwachsDAntipsychotic treatment patterns and hospitalizations among adults with schizophreniaSchizophr Res20081011–330431118255270
   PubMed Web of Science ®Google Scholar
• AhnJMcCombsJSJungCClassifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) programValue Health2008111485618237360
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and QualityHCUP facts and figures: statistics on hospital-based care in the United States, 2008Rockville, MDAgency for Healthcare Research and Quality2010 Available from: http://www.hcup-us.ahrq.gov/reports.jspAccessed July 6, 2013
   Google Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry200418434635115056580
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationAmerican Psychiatric AssociationAmerican Association of Clinical EndocrinologistsNorth American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesDiabetes Care200427259660114747245
   PubMed Web of Science ®Google Scholar
• McEvoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res2005801193216137860
   PubMed Web of Science ®Google Scholar
• BreseeLCMajumdarSRPattenSBJohnsonJAPrevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based studySchizophr Res20101171758220080392
   PubMed Web of Science ®Google Scholar
• MathewsMMuzinaDJAtypical antipsychotics: new drugs, new challengesCleve Clin J Med200774859760617708131
   PubMed Web of Science ®Google Scholar
• SernyakMJLeslieDLAlarconRDLosonczyMFRosenheckRAssociation of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophreniaAm J Psychiatry2002159456156611925293
   PubMed Web of Science ®Google Scholar
• WeidenPJMackellJAMcDonnellDDObesity as a risk factor for antipsychotic noncomplianceSchizophr Res2004661515714693352
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• VelliganDILamYWGlahnDCDefining and assessing adherence to oral antipsychotics: a review of the literatureSchizophr Bull200632472474216707778
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychoticInt J Clin Pract201165218921021129135
   PubMed Web of Science ®Google Scholar
• RajagopalanKO’DayKMeyerKTime-on-therapy for atypical antipsychotics in a Markov cohort analysisAbstract PMH86 presented at the International Society for Pharmacoeconomics and Outcomes Research Annual International MeetingJune 2–6, 2012Washington, DC
   Google Scholar
• Bureau of Labor StatisticsConsumer Price Index, All Urban Consumers Available from: http://data.bls.gov/cgi-bin/surveymost?cuAccessed July 6, 2013
   Google Scholar
• MullinsCDDouble counting and the reporting of cost per event avoidedClin Ther200628460260316750471
   PubMed Web of Science ®Google Scholar
• NasrallahHASilvaRPhillipsDLurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled studyJ Psychiatr Res201347567067723421963
   PubMed Web of Science ®Google Scholar
• MeltzerHYCucchiaroJSilvaRLurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled studyAm J Psychiatry2011168995796721676992
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBSrVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham Heart StudyCirculation2008117674375318212285
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJXuJSarmaKPikalovAKaneJMEffectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority studySchizophr Res201314719510223583011
   PubMed Web of Science ®Google Scholar
• ChrzanowskiWKMarcusRNTorbeynsANyilasMMcQuadeRDEffectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapinePsychopharmacology2006189225926617058105
   PubMed Web of Science ®Google Scholar
• KahnRSSchulzSCPalazovVDStudy 132 InvestigatorsEfficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768683284217592906
   PubMed Web of Science ®Google Scholar
• McEvoyJPLiebermanJAStroupTSCATIE InvestigatorsEffectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatmentAm J Psychiatry2006163460061016585434
   PubMed Web of Science ®Google Scholar
• McDermottSMoranRPlattTIsaacTWoodHDasariSHeart disease, schizophrenia, and affective psychoses: epidemiology of risk in primary careCommunity Ment Health J200541674775516328587
   PubMed Web of Science ®Google Scholar
• LeslieDLRosenheckRAIncidence of newly diagnosed diabetes attributable to atypical antipsychotic medicationsAm J Psychiatry200416191709171115337666
   PubMed Web of Science ®Google Scholar
• AriasEUnited States life tables, 2007National vital statistics reportsHyattsville, MDNational Center for Health Statistics2011 Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_09.pdfAccessed July 6, 2013
   Google Scholar
• HorKTaylorMReview: suicide and schizophrenia: a systematic review of rates and risk factorsJ Psychopharmacol201024Suppl 4819020923923
   PubMed Web of Science ®Google Scholar
• O’SullivanAKRubinJNyamboseJKuznikACohenDJThompsonDCost estimation of cardiovascular disease events in the USPharmacoeconomics201129869370421585226
   PubMed Web of Science ®Google Scholar
• RedBook OnlineMicromedex 2.0, Thomson ReutersAccessed October 9, 2012
   Google Scholar
• Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry2010102 Available from: http://www.micromedexsolutions.com/home/dispatch20059765
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationEconomic costs of diabetes in the US in 2007Diabetes Care200831359661518308683
   PubMed Web of Science ®Google Scholar
• RajagopalanKHassanMO’DayKMeyerKGrossmanFCost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial dataJ Med Econ201316795196123701260
   PubMedGoogle Scholar
• FuriakNMAscher-SvanumHKleinRWCost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesCost Eff Resour Alloc20097419351408
   PubMedGoogle Scholar
• McIntyreRSCraginLSorensenSNaciHBakerTRoussyJPComparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysisJ Eval Clin Pract201016474475520545800
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHStenslandMDPengXCost-effectiveness of olanzapine vs aripiprazole in the treatment of schizophreniaCurr Med Res Opin201127111512221110749
   PubMed Web of Science ®Google Scholar
• CooperDMoisanJAbdousBGrégoireJPA population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophreniaCan J Clin Pharmacol2008153e385e39718953083
   PubMedGoogle Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric AssociationSteering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• KreyenbuhlJBuchananRWDickersonFBDixonLBSchizophrenia Patient Outcomes Research Team (PORT)The schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009Schizophr Bull20103619410319955388
   PubMed Web of Science ®Google Scholar
• NaberDLambertMThe CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansCNS Drugs200923864965919594194
   PubMed Web of Science ®Google Scholar
• BuchananRWKreyenbuhlJKellyDLSchizophrenia Patient Outcomes Research Team (PORT)The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• LlorenteMDUrrutiaVDiabetes, psychiatric disorders, and the metabolic effects of antipsychotic medicationsClin Diabetes20062411824
   Google Scholar
• PatelKHHlavinkaPFSchizophrenia: optimal therapy with second-generation antipsychotic agentsPharmacy Today200713117184
   Google Scholar
• CitromeLNasrallahHAOn-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does notExpert Opin Pharmacother201213111599161322017361
   PubMed Web of Science ®Google Scholar
• Latuda (lurasidone HCl) [package insert]Marlborough, MASunovion Pharmaceuticals Inc2010
   Google Scholar